SG&A Expense (TTM) Chart

View SG&A Expense (TTM) for ELAN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (TTM) Chart
Start Trial

Historical SG&A Expense (TTM) Data

View and export this data back to 2018. Start Trial.
Date Value
June 30, 2026 1.519B
March 31, 2026 1.47B
December 31, 2025 1.43B
September 30, 2025 1.392B
June 30, 2025 1.364B
March 31, 2025 1.318B
December 31, 2024 1.314B
September 30, 2024 1.306B
June 30, 2024 1.296B
March 31, 2024 1.295B
December 31, 2023 1.285B
September 30, 2023 1.296B
June 30, 2023 1.281B
March 31, 2023 1.271B
December 31, 2022 1.267B
September 30, 2022 1.291B
June 30, 2022 1.335B
Date Value
March 31, 2022 1.377B
December 31, 2021 1.402B
September 30, 2021 1.449B
June 30, 2021 1.385B
March 31, 2021 1.163B
December 31, 2020 996.60M
September 30, 2020 808.40M
June 30, 2020 723.00M
March 31, 2020 761.10M
December 31, 2019 760.20M
September 30, 2019 759.40M
June 30, 2019 746.10M
March 31, 2019 736.30M
December 31, 2018 735.20M
September 30, 2018 550.10M
June 30, 2018 371.10M
March 31, 2018 180.00M

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
Eli Lilly & Co. 12.24B
Zoetis, Inc. 2.378B
ANI Pharmaceuticals, Inc. 324.76M
EyePoint, Inc. 55.41M
Amylyx Pharmaceuticals, Inc. 69.66M